Boehringer Ingelheim is a leading research-driven biopharmaceutical company. Making new and better medicines for patients is at the heart of what we do. As an independent company, we have the freedom to follow our long-term vision, which allows us to lead the science and create first-in-class discoveries that change lives. Our dedicated scientists are doing just that. They’re tackling some of the most difficult challenges in healthcare and together, with our external research partners, they are working to accelerate treatments that will transform patients’ lives – now and for generations to come. Our vision is powered by innovation. Our industry-leading investment in R&D drives this, with a portfolio that is anchored by more than 50 new medical entities. In 2024, we reached 66 million patients and we invested 27.6% of our Human Pharma net sales back into R&D, one of the largest commitments in our industry. For more information, visit www.boehringer-ingelheim.com.